Cosmo Pharmaceuticals N.V. (ETR:C43)
Germany flag Germany · Delayed Price · Currency is EUR
58.00
+0.50 (0.87%)
Last updated: Mar 27, 2025

Cosmo Pharmaceuticals Statistics

Total Valuation

ETR:C43 has a market cap or net worth of EUR 961.59 million. The enterprise value is 829.86 million.

Market Cap 961.59M
Enterprise Value 829.86M

Important Dates

The last earnings date was Thursday, March 6, 2025.

Earnings Date Mar 6, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class n/a
Shares Outstanding n/a
Shares Change (YoY) +1.94%
Shares Change (QoQ) +3.31%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 8.52M

Valuation Ratios

The trailing PE ratio is 7.22.

PE Ratio 7.22
Forward PE n/a
PS Ratio n/a
PB Ratio n/a
P/TBV Ratio 3.08
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.24, with an EV/FCF ratio of 5.26.

EV / Earnings 6.23
EV / Sales 3.16
EV / EBITDA 5.24
EV / EBIT 5.67
EV / FCF 5.26

Financial Position

The company has a current ratio of 4.19, with a Debt / Equity ratio of 0.00.

Current Ratio 4.19
Quick Ratio 3.39
Debt / Equity 0.00
Debt / EBITDA 0.01
Debt / FCF 0.01
Interest Coverage 2,809.09

Financial Efficiency

Return on equity (ROE) is 29.31% and return on invested capital (ROIC) is 20.39%.

Return on Equity (ROE) 29.31%
Return on Assets (ROA) 15.87%
Return on Invested Capital (ROIC) 20.39%
Return on Capital Employed (ROCE) 24.88%
Revenue Per Employee 828,534
Profits Per Employee 413,776
Employee Count 322
Asset Turnover 0.45
Inventory Turnover 3.27

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -18.88% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change -18.88%
50-Day Moving Average 64.75
200-Day Moving Average 71.05
Relative Strength Index (RSI) 45.79
Average Volume (20 Days) 41

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, ETR:C43 had revenue of EUR 266.79 million and earned 133.24 million in profits. Earnings per share was 8.12.

Revenue 266.79M
Gross Profit 221.43M
Operating Income 148.88M
Pretax Income 153.37M
Net Income 133.24M
EBITDA 160.47M
EBIT 148.88M
Earnings Per Share (EPS) 8.12
Full Income Statement

Balance Sheet

The company has 142.96 million in cash and 2.20 million in debt, giving a net cash position of 140.76 million.

Cash & Cash Equivalents 142.96M
Total Debt 2.20M
Net Cash 140.76M
Net Cash Per Share n/a
Equity (Book Value) 505.09M
Book Value Per Share 31.12
Working Capital 153.99M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 162.41 million and capital expenditures -4.55 million, giving a free cash flow of 157.86 million.

Operating Cash Flow 162.41M
Capital Expenditures -4.55M
Free Cash Flow 157.86M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 83.00%, with operating and profit margins of 55.81% and 49.94%.

Gross Margin 83.00%
Operating Margin 55.81%
Pretax Margin 57.49%
Profit Margin 49.94%
EBITDA Margin 60.15%
EBIT Margin 55.81%
FCF Margin 59.17%

Dividends & Yields

This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 3.45%.

Dividend Per Share 2.00
Dividend Yield 3.45%
Dividend Growth (YoY) n/a
Years of Dividend Growth 2
Payout Ratio 24.09%
Buyback Yield -1.94%
Shareholder Yield 1.51%
Earnings Yield 13.86%
FCF Yield 16.42%
Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

ETR:C43 has an Altman Z-Score of 7.21.

Altman Z-Score 7.21
Piotroski F-Score n/a